title: Patient-Derived Prostate Cancer: from Basic Science to the Clinic.
abstract: Systems that model cancer form the backbone of research discovery, and their accuracy and validity are a key determinant to ensure successful translation. In many tumour types, patient-derived specimens are an important model of choice for pre-clinical drug development. In this review, we consider why this has been such a challenge for prostate cancer, resulting in relatively few patient-derived xenografts (PDXs) of prostatic tumours compared to breast cancers, for example. Nevertheless, with only a few patient specimens and PDXs, we exemplify in three vignettes how important new clinical insights were obtained resulting in benefit for future men with prostate cancer.
authors.affiliation: Monash Partners Comprehensive Cancer Consortium and Cancer Program, Biomedicine Discovery Institute, Department of Anatomy and Developmental Biology, Monash University, Wellington Road, Melbourne, VIC, 3800, Australia. gail.risbridger@monash.edu.
authors.forename: Gail P
authors.initials: GP
authors.lastname: Risbridger
authors.affiliation: Monash Partners Comprehensive Cancer Consortium and Cancer Program, Biomedicine Discovery Institute, Department of Physiology, Monash University, Wellington Road, Melbourne, VIC, 3800, Australia.
authors.forename: Renea A
authors.initials: RA
authors.lastname: Taylor
mesh_terms: D000818:Animals; D006085:Graft Survival; D006801:Humans; D008297:Male; D009368:Neoplasm Transplantation / Q000379:methods*; D011471:Prostatic Neoplasms / Q000473:pathology*; D014183:Transplantation, Heterologous / Q000379:methods*